Doximity (NYSE: DOCS) experienced a dramatic surge in its stock price on Friday, closing at $27.40 after a volatile session that saw shares reach as high as $40. The 32.6% jump added approximately $1.21 billion to the company's equity value, driven by investor enthusiasm over the potential of its AI-driven products. However, the rally has sparked a sharp divide among Wall Street analysts, with some questioning the sustainability of the gains.
AI Revenue Prospects Fuel Rally
The surge came after Doximity's management outlined promising opportunities for AI Search and other AI-powered features, which they believe could generate significant revenue in the coming quarters. Despite the excitement, these AI revenues have not yet appeared in the company's published financial results. The market's reaction suggests investors are betting on future growth, but the actual impact on earnings remains to be seen.
The company's updated fiscal 2027 guidance reflected only a modest $6 million increase in the revenue midpoint, to $676 million, representing a 0.9% rise. Meanwhile, the adjusted EBITDA midpoint was lowered by $10 million to $319 million, implying a margin contraction from 49.1% to 47.2%. This implies that Friday's stock move represented roughly $202 in additional equity value for each dollar of raised guidance, a metric that highlights the market's forward-looking optimism.
Mixed Q1 Results
Doximity's fiscal first-quarter results were mixed. Revenue came in at $156.6 million, beating consensus estimates by about $4.9 million, but adjusted earnings per share of $0.29 missed by a cent. Adjusted EBITDA declined 6% year-over-year to $74.8 million, and free cash flow fell 34% to $39.6 million. The company attributed higher costs to AI hosting, software, and amortization, which drove revenue costs up 50% and research expenditure up 44%.
Analyst Reactions Split
The stock's surge prompted a flurry of analyst actions. Wells Fargo downgraded Doximity to Underweight from Equal Weight, maintaining an $18 price target, citing that AI monetization "looks unproven." In contrast, Needham raised its price target to $41 from $27, and Piper Sandler lifted its target to $47 from $42, both maintaining positive ratings. Raymond James and BMO Capital Markets also increased their targets, reflecting a range of views on the company's AI potential.
Overall, the analyst community remains cautious. Of 21 analysts covering the stock, nine rate it a Buy, eleven a Hold, and one a Sell. The consensus price target stands at $29.41, with a wide range from $18 to $47, underscoring the uncertainty surrounding the AI narrative.
Trading Volatility and Risks
Friday's trading was turbulent, with shares soaring 93.6% above Thursday's close before retreating to close 31.5% below their peak. Volume was heavy at 64.9 million shares. Despite the volatility, the stock advanced 31% over the week. The drop from the intraday high reflects profit-taking and the inherent risks of a headline-driven rally.
Investors should be aware of several risks. The AI Search feature may simply reallocate existing pharmaceutical budgets rather than expand them. Margins and free cash flow are already declining. Moreover, success in benchmarks like NOHARM does not guarantee that users will pay for the AI tools. The stock's premium valuation could be vulnerable if the AI revenue fails to materialize as quickly as hoped.
Market Context and Outlook
Doximity's surge comes ahead of key economic data releases this week, including July CPI on Wednesday, PPI on Thursday, and retail sales on Friday. An uptick in yields could weigh on high-valuation growth stocks like Doximity. The company's CEO, Jeff Tangney, highlighted that Doximity Ask ranked as the "top-performing U.S.-based model" on the NOHARM benchmark, and noted a 30% increase in workflow active prescribers and a 25% sequential rise in AI Search queries.
As the market digests the AI narrative, investors will be watching for concrete revenue contributions from AI products in the coming quarters. The company's ability to convert user engagement into monetization will be crucial in justifying the current valuation. Until then, the stock is likely to remain volatile, with analyst opinions sharply divided.
